

# New Agreement Brings Breakthrough Dyslipidemia Treatment to Saudi Arabia and MEA

*Strategic partnership between Jamjoom Pharma and Althera Laboratories will bring an innovative, dual-action cholesterol therapy to the region.*



Logo Althera

DUBLIN, DUBLIN, IRELAND, August 6, 2025 /EINPresswire.com/ -- Jamjoom

Pharma, a leading Saudi pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products across MEA, and [Althera Laboratories](#), a company dedicated to developing and commercializing innovative therapies for cardiovascular and metabolic diseases,

today announced a strategic licensing and supply agreement. This agreement is poised to address the growing need for effective dyslipidemia management in the region, contributing to better patient outcomes and cardiovascular health.

“

Cardiovascular diseases remain to be a leading health concern in Saudi Arabia and the wider MEA region. This partnership enables us to provide patients across the region with an innovative solution.”

*Dr. Tarek Hosni*

Under this agreement, Jamjoom Pharma gets exclusive rights to commercialize in Saudi Arabia and non-exclusive rights for phased expansion across other MEA markets for Althera's fixed-dose combination of dual-action cholesterol-lowering therapy. The product launch in Saudi Arabia is targeted for 2027, with plans for phased

expansion across MEA markets, subject to local regulatory approvals.

This collaboration marks a major milestone for both companies: Jamjoom strengthens its cardiovascular portfolio with a globally recognized and clinically effective therapy, while Althera expands its international footprint in a high-growth region.

The partnership aims to address the region's growing burden of cardiovascular diseases by increasing access to modern, affordable lipid-lowering treatment, to support patients across MEA.

Da Luz Mathieu  
Althera Laboratories  
+41 78 251 56 67

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/837220842>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.